Business Wire

Kalray and 2CRSi Join Forces and Demonstrate Composability at SuperComputing 2019

Share

Kalray (Paris:ALKAL), pioneer in processors for new intelligent systems, and 2CRSi (Paris:2CRSi), a leader in the design and manufacturing of very high-performance IT servers announce today that companies are leveraging their mutual technology and expertise to build composable and scalable server appliances.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005632/en/

Combined expertise for real synergy
Kalray’s reconfigurable acceleration solutions provide the opportunity for 2CRSi to expand its offer for the highly diversified enterprise datacenter market, including Small and Medium Businesses. There is a demanding and evolving need for flexibility, computing performance and fast integration, requiring easy to deploy reconfigurable solutions. With a unique architecture, Kalray’s programmable acceleration cards based on MPPA® (“Massively Parallel Processor Array”) can run real-time and compute-intensive applications on the same card and be seamlessly reconfigured during its lifetime in the field.

Through this collaboration, 2CRSi is strengthening its strategy to rapidly build tailor-made high-performance computing solutions for high-growth domains such as video surveillance, defect detection, finance algorithm optimization, Artificial Intelligence and many others.

One single card – Multiple configurations
Kalray’s MPPA manycore intelligent processor is making the KONIC™ PCIe cards fully programmable and easily reconfigurable, supporting addition, removal, or modification of optimized software modules as required during the lifetime of the card. Such module reconfiguration could include a mix of AI engines, application acceleration or protocol stacks.
Using a standard and open programmable development environment, this brings true composability and flexibility to expert system integrators such as 2CRSi.

Alain Wilmouth, CEO of 2CRSi explained: “2CRSi is always eager to develop innovative technology and provide state-of-the-art solutions. We are very excited to leverage Kalray’s technology. Starting with this demonstration at Supercomputing 2019, we want to further explore what composable and flexible solutions can be built to satisfy our customers. ultimately resulting in an optimized Total Cost of Ownership.”

Éric Baissus, CEO of Kalray commented: “2CRSi is one the most innovative solution providers delivering best in class server solutions in terms of cost, compute and power consumption. We are glad to contribute to 2CRSi’s offering with our KONIC reconfigurable cards and to enable 2CRSi to rapidly build the best solutions for their Customers.”

Demonstration at SuperComputing 2019
2CRSi and Kalray will showcase three different software configurations of the same KONIC™ reconfigurable PCIe card integrated into a dual-x86 server built by 2CRSi:

  • Multiple and heterogenous AI Inference engines (“Multi-CNN”);
  • Flexible multi-acceleration - Example of Fast Fourier Transform (FFT) acceleration;
  • High performance storage disaggregation using Kalray’s Target Controller (“KTC™”) for low latency access to high density JBOF (“Just a Bunch of Flash”).

For more information and to view the demonstrations, come and visit us at SuperComputing,
the international conference for high performance computing, networking, storage, and
Analysis, from November 18 to 21 at Colorado Convention Center, Denver, USA:
Kalray’s booth #2205 and 2CRSi booth #1801

À propos de Kalray
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is the pioneer in processors for new intelligent systems. A genuine technological breakthrough, “intelligent” processors are able to intelligently analyze a vast quantity of data on the fly and to make decisions and interact in real time with the outside world. These intelligent processors will be largely deployed in fast-growing sectors such as new-generation networks (intelligent data centers) and autonomous vehicles, as well as in healthcare equipment, drones and robots. Kalray’s offering spans both processors and global solutions (electronic boards and software). Created in 2008 as a spin-off of CEA (“Commissariat à l’Énergie Atomique”, the French Alternative Energies and Atomic Energy Commission), Kalray addresses a broad spectrum of customers including server manufacturers, intelligent system integrators and consumer product manufacturers such as car makers.
Read more at: www.kalrayinc.com

À propos de 2CRSi
2CRSi is headquartered in Strasbourg, France, and has subsidiaries in Manchester, UK, Dubai, UAE, and San Jose in the Silicon Valley. It specializes in the design and manufacturing of very high-performance IT servers. It provides innovative calculation, data storage and data transfer solutions to over 200 various clients in 25 countries.
Read more at: www.2crsi.com

Contact information

CONTACTS FOR KALRAY
INVESTORS
Eric BAISSUS
contactinvestisseurs@kalray.eu
+33 (0)76 18 90 71

ACTUS finance & communication
Caroline LESAGE
kalray@actus.fr
+33 (0)1 53 67 36 79

MEDIA
Loic HAMON
communication@kalray.eu
+33 ()04 76 18 90 71

ACTUS finance & communication
Serena BONI
sboni@actus.fr
+33 (0)4 72 18 04 92

CONTACTS FOR 2CRSi
INVESTORS
Valérie Bouleau
Chief Financial Officer
investors@2crsi.com
+33 (0)3 69 73 81 30

Actifin
Victoire Demeestère
Financial Communication
vdemeestere@actifin.fr
+ 33 (0)1 56 88 11 24

MEDIA
Actifin
Jennifer Jullia
jjullia@actifin.fr
+ 33 (0)1 56 88 11 19

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 22:00:00 EETPress release

Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 18:20:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma

Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 18:18:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu

Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 17:30:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu

Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 21:07:00 EETPress release

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer

BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 16:00:00 EETPress release

BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom